Table 5 Risk of Alzheimer’s disease by various exposure criteria of strong anticholinergic agents in the all subjects and young-old subgroup.
Prescribed amount* (doses/year) | All subjects (n = 191,805) | Young-old subgroup (n = 84,566) | |||
|---|---|---|---|---|---|
No. of AD events (%) | HR (95% CI) | No. of AD events (%) | HR (95% CI) | ||
Total strong anticholinergic agents- recent 1 year† | 0–9 | 6,327 (6.3) | Reference | 1,137 (2.5) | Reference |
10–49 | 4,539 (6.6) | 0.95 (0.92–0.98) | 941 (3.1) | 1.05 (0.96–1.15) | |
50–119 | 1,351 (9.4) | 1.13 (1.06–1.20) | 259 (4.9) | 1.31 (1.13–1.51) | |
≥120 | 916 (11.9) | 1.32 (1.22–1.42) | 208 (7.7) | 1.74 (1.47–2.05) | |
Total strong anticholinergic agents- recent 2 year‡ | 0–9 | 8,019 (6.3) | Reference | 1,508 (2.6) | Reference |
10–49 | 3,448 (7.2) | 0.99 (0.95–1.03) | 689 (3.4) | 1.04 (0.95–1.14) | |
50–119 | 881 (9.6) | 1.03 (1.10–1.19) | 185 (5.7) | 1.35 (1.15–1.58) | |
≥120 | 785 (11.5) | 1.23 (1.14–1.33) | 160 (6.6) | 1.37 (1.15–1.63) | |
Total strong anticholinergic agents- antidepressants | 0–24 | 9,449 (6.3) | Reference | 1,808 (2.6) | Reference |
25–59 | 2,104 (8.1) | 1.10 (1.05–1.15) | 430 (4.0) | 1.20 (1.07–1.33) | |
≥60 | 1,580 (10.5) | 1.24 (1.18–1.32) | 304 (5.9) | 1.41 (1.23–1.61) | |
Antihistamines | 0–49 | 11,898 (6.6) | Reference | 2,339 (2.9) | Reference |
≥50 | 1,235 (10.1) | 1.12 (1.05–1.19) | 203 (5.0) | 1.09 (0.94–1.27) | |
Antidepressants | 0–9 | 11,668 (6.6) | Reference | 2,165 (2.7) | Reference |
≥10 | 1,465 (10.8) | 1.36 (1.29–1.44) | 377 (6.9) | 1.74 (1.55–1.96) | |
Urinary antimuscarinics | 0–2 | 11,565 (6.7) | Reference | 2,222 (2.8) | Reference |
≥3 | 1,568 (9.6) | 1.31 (1.24–1.38) | 320 (5.0) | 1.42 (1.26–1.61) | |
